scholarly journals Lipid profile in children of β-thalassemia major and their correlation with serum ferritin

2017 ◽  
Vol 4 (2) ◽  
pp. 543 ◽  
Author(s):  
Rameshwar L. Suman ◽  
Anuradha Sanadhya ◽  
Pradeep Meena ◽  
Jaskaran Singh ◽  
Rupali Jain ◽  
...  

Background: β-thalassemia major is a secondary iron load state. The high serum ferritin accounts for abnormal lipid profile. This study was done to investigate the lipid profile in children with β-thalassemia major and to know their correlation with serum ferritin.Methods: Fifty-five (55) children of beta thalassemia major in the age group of 4-20 years from thalassemia unit of tertiary care hospital who were on regular blood transfusion and oral iron chelators were enrolled. Serum ferritin levels and lipid profile of these children were investigated and their correlation was assessed. Results: Out of total 55 children 31 (56.4%) children were of female sex and 48(87.3%) were Hindu by religion. The mean rate of blood transfusion was 157.02±21.33 ml/kg/year with average dose and duration of iron chelation with Desferroxamine was 34.4±26.86 mg/kg /day and 2.34±1.86 years respectively. Mean cholesterol level, high density lipoprotein (HDL), low density lipoprotein (LDL) levels were on lower side of the range with values of 124.47±19.81 mg/dl, 36.58±12.22 mg/dl, 63.94±4.57 mg/dl respectively. The mean triglyceride level (TG) was on higher side with an average of 142.93±33.7 mg/dl. The average serum ferritin levels were 2130.33±859.85 ng/ml. There was negative correlation of total cholesterol, HDL, LDL with serum ferritin with coefficient of correlation (r= -0.77, -0.55, -0.72) respectively. The serum triglyceride had positive correlation with serum ferritin with coefficient of correlation(r=+0.85).Conclusions: As the serum ferritin increases, there occurs more derangement of lipid profile in form of decreasing serum cholesterol, HDL, LDL and increasing serum TG levels.

Author(s):  
Saikat Nandi ◽  
Sanjana Samanta ◽  
Tanushree Mondal ◽  
Sanjay Halder

Background: β-Thalassemia major is associated with iron overload toxicity. This study was done to investigate lipid profile abnormality in β-Thalassemia major patients and to establish their correlation with serum ferritin. Another motto of this study was to signify deleterious effect of multiple blood transfusion and facilitate to understand how it will affect the lipid profile parameters changes so that we can also prevent early dyslipidemia induced complications like atherogenesis by early detection of lipid profile abnormality and also to establish derangement of lipid profile as an indirect evidence of iron overload.Methods: 102 nos. β-Thalassemia major paediatric patients with multiple blood transfusion (≥10) in age group of 6 to12 years admitted in pediatric ward of tertiary care hospital (NRSMCH) were enrolled. Serum ferritin level and lipid profile were investigated and their correlation were assessed.Results: Among 102 β-Thalassemia major pediatric (6 to 12 years) patients 55.88% were male and 66.67% were Hindu by religion and 69.61% children came from lower socio-economic class. The average value of number of previous blood transfusion was 42.79±7.510. The mean value of serum ferritin was 2263.53±833.904 ng/ml. The average value of serum total cholesterol, LDL and HDL were 153.84±5.428 mg/dl and 97.16±3.982 mg/dl and 29.45±4.445 mg/dl respectively and their correlation with serum ferritin were negative (r=-0.941 and r=-0.964 and r=-0.751 respectively). Average value of serum triglyceride and VLDL were 206.22±67.407 mg/dl and 36.16±3.385 mg/dl respectively and their correlation with serum ferritin were positive (r=+0.606 and r=+0.973 respectively).Conclusions: There was significant lipid profile derangement. As the serum ferritin level increases, serum total cholesterol, HDL, LDL decreases and serum triglyceride, VLDL level increases.


Author(s):  
Urooj Zafar ◽  
Jahan Ara Hassan ◽  
Kauser Ismail ◽  
Shanza Agha ◽  
Zahida Memon ◽  
...  

Background: Polycystic ovary syndrome (PCOS) is a heterogeneous metabolic disorder affecting women of the child-bearing age. Alteration in lipid profile is one of the troublesome features faced by PCOS patients that need to be treated. Aim: The purpose of this study was to compare the effects of Probiotics, Metformin and their Combination therapy on lipid profile in women suffering from PCOS. Study Design: Single-Centered Randomized Controlled Trial. Setting: Gynecological clinic of Karachi at Tertiary care Hospital from December 2018 to May 2019. Patients and Methods: Total 78 PCOS patients of age between 18 to 40 years were involved in this trial rendering to Rotterdam criteria. After taking written and informed consent they were randomly allocated to three groups and were received: Metformin 500 mg B.D (n = 26), Probiotic Capsule 180 mg B.D (n = 26) and Combination of Metformin 500 mg B.D / Probiotic Capsule 180 mg B.D for 12-weeks. Lipid profile was measured at baseline and after 12-weeks of intervention along with the body weight. In the end, pre versus post therapy and comparison of different group’s results were analyzed. Results: Metformin and Met/Pro Combination groups resulted in a significant reduction in Total Cholesterol (TC) as compared to Probiotic group. Fall in Low-Density Lipoprotein Cholesterol (LDL-C) levels were noteworthy after Probiotics and Met/Pro treatment. Serum TG concentrations were significantly reduced in all the groups. High-Density Lipoprotein Cholesterol (HDL-C) levels were slightly elevated after Probiotics treatment, which was not statistically significant but Metformin and Met/Pro group increases it to the significant value. No substantial change was found in the Very Low-Density Lipoprotein Cholesterol VLDL-C levels in any of the three groups. Conclusion: Overall, Probiotics treatment in PCOS women for 12 weeks exhibited noteworthy changes in TG, and LDL-C levels. Metformin markedly improve Cholesterol, TG and HDL-C. However, Met/Pro improved all the lipid changes to the significant value except for VLDL-C.


2019 ◽  
Vol 35 (3) ◽  
Author(s):  
Arshad Hussain ◽  
Iftikhar Ali ◽  
Waqar Ahmad Kaleem ◽  
Fatima Yasmeen

Objective: To determine the correlation between body mass index (BMI) and lipid profile in patients with Type 2 Diabetes Mellitus (T2DM) attending a tertiary care hospital in Peshawar. Methods: A total of 305 patients (men, 132; women, 173) with T2DM visiting an Outpatient department in Northwest General Hospital and Research Centre, Peshawar from January 2016 to July 2016 were included in this study. The whole blood and sera were analyzed for Glycated hemoglobin (HbA1c), total cholesterol (TC), triglyceride (TGs), high density lipoprotein cholesterol (HDL-C) and low density lipoprotein cholesterol (LDL-C).The correlation of BMI with lipid ratios and individual lipid indices were analysed. Results: Mean of BMI was 29.29±5.23. Dyslipidemia; increased TC, increased LDL-C, increased triglyceride and decreased HDL-C were noted in 40.7%, 54.1%, 69.5% and 41% respectively. The mean difference of LDL-C (p=0.006) was significant between male and female. BMI, TC, TGs, and LDL-C showed no significant correlation where as a significant negative correlation between BMI and HDL-C was observed(r=-0.125, p=0.029, R2=0.016). The mean values of TC, TG, LDL-C, TC/ HDL-C and LDL-C/HDL-C ratios were greater in patients with normal BMI compared to overweight and obese; however, the differences were not significant. HDL-C differed significantly in BMI groups (p=0.040). Conclusion: A significant negative correlation between BMI and HDL-C was observed, while the correlation between BMI and LDL-C was observed to be insignificant. HDL-C was found significantly higher in patients with normal BMI. These results are important to indicate that there is modest impact of BMI on lipid profile. Therefore, assessment and management for altered blood lipids should not be based on a patient’s body weight or BMI. doi: https://doi.org/10.12669/pjms.35.3.7 How to cite this:Hussain A, Ali I, Kaleem WA, Yasmeen F. Correlation between Body Mass Index and Lipid Profile in patients with Type 2 Diabetes attending a tertiary care hospital in Peshawar. Pak J Med Sci. 2019;35(3):---------. doi: https://doi.org/10.12669/pjms.35.3.7 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


2020 ◽  
Vol 42 (3) ◽  
pp. 32-37
Author(s):  
Binod Raut ◽  
Nimesh Paudel ◽  
Deepti Shrestha ◽  
Anant Bhosekar

Introduction Hyperlipidemia is one of the most contributing factors to coronary heart diseases. Statins have become standard medicine in clinical practice to reduce total cholesterol, low density lipoprotein and to increase high density lipoprotein cholesterol. This study is conducted to compare the effectiveness and safety of atorvastatin with rosuvastatin in hyperlipidemic patients. MethodsThis is a prospective observational study involving 150 patients conducted in the Department of Internal Medicine of Kathmandu Medical College and Teaching Hospital from July 2019 to March 2020. Patients newly diagnosed with hyperlipidemia were enrolled. Patients that were prescribed with 10 mg of atorvastatin and 5 mg of rosuvastatin by the treating physician once daily for 6 weeks were divided into two groups. Data was recorded in the customized proforma and the SPSS package version 20 was used for analysis. ResultsPatients that were prescribed with atorvastatin were put in group I and those prescribed with rosuvastatin were included in group II with 75 participants in each group. The mean age of the patients were 50.56± 10.08 years in group I and 52.45±10.20 years in group II with male to female ratio of 3:1. The mean BMI of group I was 25.36±1.74 and that of group II was 26.48±2.21 before therapy. There was a significant main effect of duration (F1,74=401.02, p<0.001) on the TG and TC levels (F1,74=1134.23, p<0.001) as well as (F1,74=614.99, p<0.001) on the LDL and HDL levels (F1,74=146.38, p<0.001). ConclusionRosuvastatin was significantly more effective than atorvastatin in reducing levels of TG, TC and LDL-C. Rosuvastatin also significantly increased the level of HDL.


2021 ◽  
Vol 8 (23) ◽  
pp. 1915-1921
Author(s):  
Supriya Sanke ◽  
Chitra Karuppiah ◽  
Hema Sundar Rao Dumpala ◽  
Sai Vishnu Vardhan Allu ◽  
Syamala Shanthi Kumari Bonela

BACKGROUND Hypertension is a silent killer, an asymptomatic chronic disorder if left untreated which results in major health problems. Goal of treatment is to decrease the morbidity and mortality associated with cardiovascular and cerebrovascular complications of hypertension when it is associated with dyslipidaemia. The renin angiotensin system plays an important role in the regulation of blood pressure and in the pathogenesis of hypertension. Telmisartan is an ARB (angiotensin receptor blocker) and Enalapril is an ACE inhibitor. The purpose of this study is to compare the efficacy of Telmisartan with Enalapril in patients of essential hypertension with dyslipidaemia, and to observe the effects of Telmisartan and Enalapril on blood lipid levels of these patients. METHODS This is a prospective, randomized, comparative and open label study conducted among 70 patients who were included in the study and were divided in to two groups. Group A - consisting of 35 patients receiving Telmisartan 40 mg, and Group B receiving Enalapril 5 mg orally once a day. Informed consent was obtained from all the patients. Follow up was done after 4, 8 and 12 weeks. Blood pressure was recorded at every visit and lipid profile was done at the time of enrolment and after 12 weeks of study period. RESULTS Baseline demographic attributes were comparable between both the groups including total cholesterol and low-density lipoprotein (LDL). The mean reduction in systolic and diastolic blood pressure (BP) after 12 weeks was highly significant (P value < 0.001) in both the groups but when mean reduction in SBP & DBP was compared, there was no significant difference (P > 0.05) between the drugs. Blood levels of total cholesterol, LDL, triglyceride had significantly reduced (P < 0.05) in Telmisartan group compared to Enalapril group after 12 weeks of follow up and mean high density lipoprotein (HDL) level significantly increased in Telmisartan group (P < 0.05) but no increment was seen in Enalapril group. CONCLUSIONS Telmisartan and Enalapril had comparable antihypertensive effect and significant reduction in blood pressure was seen after 12 weeks of therapy in both the groups. In addition, Telmisartan showed more beneficial effects on lipid profile when compared to Enalapril. KEYWORDS Hypertension, Dyslipidemia, Lipid Profile, Telmisartan, Enalapril


Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 4936-4936
Author(s):  
Mukesh Manharlal Desai ◽  
Harvinder Iqbal Palaha ◽  
Snehal Desai ◽  
Manisha Madkaikar ◽  
Bharat Agarwal ◽  
...  

Abstract Abstract 4936 We present a retrospective analysis of HLH diagnosed at B J Wadia Hospital for Children, a tertiary care exclusive pediatric institute in Mumbai. In all, 43 cases were diagnosed as HLH as per 2009 Guidelines (Filipovich et al). There were 15 (34.9%) males and 28 (63.1%) females. The mean age was 3 yrs 4 mths with a range of 15 days to 12 yrs. The commonest presenting symptom was fever in 85% of cases. RS, GI, Renal and CNS symptoms were seen in 48.8%, 65%, 11.6% and 24% of our cases. Skin pigmentation, Petachiae, Oedma and arthritis was present in 12(27.9%); 4(9.3%), 13(30.2%), and 4(9.3%) of cases respectively. 41(95.3%) babies had Hepatomegaly while 35(81.3%) had Splenomegaly. Lymphadenopathy was seen in 13(30.2%). 12 (27.9%) had pigmentation, 13(30.2%0 had oedema while 4 (9.3%) each had petachiae and arthritis. Mean Hb of 8.2 gm/dl and a range of 3.5 to 10 gm/dl. The Mean WBC count & ANC were 8030 (range 1300 – 29400) & 4614 (300-19400). 37(86%) had thrombocytopenia. Liver injury 27(62.7%), hyponatremia 28(65.1%) and renal failure in 6(13.95%) was seen at diagnosis. Coagulopathy was present in 38(88.4%) and serum ferritin was >500 in 36(83.7%) with a mean of 26135 ng/ml and range of 82 to 200,000 ng/ml. 24(55.8) cases had Hypertriglyceridemia with mean levels of 236. 13 patients had infections 6 UTI & 7 bacterial diarrhoea. Only 2 out of 16 children had CSF abnormality at diagnosis. BM was hypo cellular in 3 and hyper cellular in 40 and all showed hemophagocytosis. PS showed HLH in 4 cases. Cultures isolated K pneumoniae in 5, P aeruginosa in 2, S. Typhi in 1, Candida in 4, and H1N1 in 1. Kalazar was the cause of HLH in 1 and 2 patients had P vivax seen on PS. 1 child had SPTCL & HLH while another child has ALCl & HLH. The child with SPTCL had gross hemophagocytosis on skin biopsy as well as in the Bone Marrow. Perforin was done in 30(70%) and was low in 6/30 (20%) cases, while GRA (Granule Release Assay) was done in 15(35%) and was abnormal in 4/15(26.6%). GRA was established last year only. In 29(67.4%) cases IAHS was diagnosed. The IAHS were, HIV 1, Post Chicken pox 1, Dengue 2, Viral aseptic meningitis 1, P vivax 1, Leishmaniasis 1, MTB in 1, S. typhi in 1, gram −ve sepsis in 8, candidia in 3, viral infection 9. 2 cases had MAS (Macrophage Activation Syndrome) with JRA; serum ferritin was as high as 200,000 ng/ml at diagnosis. 1 child had Griscelli Syndrome with HLH. Perforin deficiency presented at a mean age of 5 mths & all had severe fulminant presentation with brief H/o of viral infection and hepatosplenomegaly. Hepatic injury was severe and rapidly progressive, CNS affection was present in 3/6 cases and all died. 2/4 children with GRA abnormalities presented early at 15 days & 1 mth of life, 1 had a gm −ve sepsis with response to HLH protocol but relapsed & Died, the other child presented with fever, hepatosplenomegaly, pancytopenia & neuroregression and BMA confirmed HLH. Of the other 2 babies with GRA abnormalities 1 was a case of Griscelli who presented at 4 yrs 6 mths of life while the other presented at 1 6 mths yr of life as what appeared like IAHS and sucumbed to his disease. 2/4 with GRA abnormalities are alive and well. 1 child had thrombocytopenia and Malena as the sole presentation of HLH and the Bone Marrow done 4 times showed gross hemophagocytosis. 2/4 children with elevated creatinine required peritoneal dialysis. All our cases received Dexa, CsA & Etoposide as in HLH 2004 protocol. We ensured that the 1st 2 doses of etoposide were given after which etoposide may be witheld depending on clinical situation. IT MTX was given when there was CSf abnormalities or gross CNS signs. The Mortality was 32.5% (14/43). 3 of them died during Follow up with relapse of HLH, 1 child with ALCL died of Lymphoma while child with SPTCL is alive but with systemic symptoms. 8/43 (18.6%) are lost to follow up. Majority of IAHS did well with treatment. 8 are presently on regular follow up. In IAHS reassesment of HLH status if normal at 8 weeks, treatment was discontinued. 21/43 children completed 8 weeks of treatment. Conclusions: HLH is not an uncommon diagnosis in tertiary care centre in India. IAHS was the commonest cause of HLH and prompt dignosis with treatment HLH 2004 protocol is necessary to control the hyperinflammation. Our Ferritin values were very high. Incidence of Perforin deficiency was 20% and 26.6% respectively. Mortality in perforin deficiency was 100%. Bacterial infection and fungal infections were also common among the IAHS. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 4899-4899 ◽  
Author(s):  
Sadia Sultan ◽  
Syed Mohammed Irfan ◽  
Rozina Zeeshan

Abstract Introduction: Serum fasting lipid profile has been studied in various clinical spectrum of β-thalassemia syndrome. Premature cardiac impairment in thalassemia major (TM) appears primarily due to iron accumulation and oxidative injury; however it might be a sequel of abnormal lipoprotein concentrations. Recent studies revealed impaired lipid profile and atherosclerosis in TM as an emerging complication in patients with prolonged survival. As these children are at risk of premature atherosclerosis, sub clinical atherosclerosis probably begins early in their life might evolve into coronary heart diseases in later life. The rational of this prospective cross sectional study is to analyze the serum fasting lipid profile in cardiovascular disease free thalassemia major patients and to establish any correlation with age, gender, hematological parameters, liver enzymes and serum ferritin. Method: The study group comprises of thirty six patients with β-thalassemia major, who were enrolled from March 2012 to March 2014. Fasting blood lipid levels (total lipid, cholesterol, triglycerides, HDL and LDL-cholesterol), liver function test and serum ferritin were measured in all study participants on Hitachi 912 through photometric assay (for lipid profile and liver function test) and by immunoturbidity methodology for serumferritin. Hematological parameters were determined by Cell Dyne Ruby (Abbot, Architect, USA). Patients were stratified in two groups, age ≤ 15 years and >15 years, to determine the possible lipid profile distinction in relation to increasing age. Results: Of the 36 patients, 17 were males (15.5±5.9 years) and 19 were females (10.1±4.5 years) with the mean age of 12.69±5.85 (range 5-24) years. Mean hemoglobin was 7.4±1.9gm/dl with the hematocrit of 23.1±5.7% while serum ferritin was markedly elevated 4699.7±3089ng/ml. The mean total lipid, cholesterol and triglycerides levels were 494.7 ± 114.5, 90.3 ±23.9 and 150.5±95.1 mg/dl respectively. High triglycerides were detected in 36.1%. While HDL cholesterol and LDL cholesterol were markedly low 17.7±9.2 and 42.3±22.0 mg/dl respectively. The mean total cholesterol to HDL ratio was significantly elevated, 6.21± 3.06 (normal <5.0). In addition, total-cholesterol to HDL-cholesterol ratios were increased irrespective of gender, that is 6.0±2.0 and 6.4± 3.8 in males and females respectively (P=0.6). Data analysis revealed that 22.2% females and 13.8% males had high triglyceride levels (P=0.05). No statistically significant difference was noted in two stratified age groups in respect to lipid profile (table-1). We established positive correlation of elevated total bilirubin with cholesterol, HDL and LDL cholesterol (P<0.05). Cholesterol ratio was also significantly high in patients with hemoglobin > 8gm/dl (P<0.05). Low HDL cholesterol was correlated positively with LDL cholesterol levels. While no significant correlation of serum lipid could be established with age, gender, high ferritins and with liver enzymes. Conclusion: Our study revealed that lipid profile impairment is not unusual in β-thalassemia major patients irrespective of age. Considerable deficiency of high density cholesterol and significantly high total-cholesterol to HDL-cholesterol ratio may strongly be associated with occurrence of coronary heart disease in later life. We propose that lipid profile should be regularly done in these patients particularly those with hemoglobin > 8gm/dl and high total bilirubin levels. Whilst total to HDL ratio, underlines as a significant diagnostic marker for future cardiac events in these patients. Keywords: β-thalassemia major, triglyceride, HDL-cholesterol, LDL-cholesterol. Table 1: Comparative analysis of serum lipid profile in relation to age Parameters Age ≤15 years n= 24 Age >15 years n= 12 P- value Total lipid 515.7± 121.1 452.9 ±90.6 0.1 * Cholesterol 95.0±17.6 80.9±32.1 0.09 * Serum triglyceride 168.1 ± 109.7 115.2± 40.1 0.1 * HDL cholesterol 19.4±10.2 14.4± 5.9 0.1 * LDL cholesterol 43.1±19.9 40.9±26.6 0.7 * Cholesterol ratio 6.3± 3.4 6.0 ±2.1 0.8 * *Not significant Disclosures No relevant conflicts of interest to declare.


2018 ◽  
Vol 5 (4) ◽  
pp. 978
Author(s):  
Tumbanatham A. ◽  
Jayasingh K. ◽  
Varun Vijayan Vijayan

Background: Subclinical hypothyroidism (SH) is characterized by elevated levels of serum thyroid stimulating hormone in the presence of normal thyroxin levels. Subclinical hypothyroidism is often associated with elevated total cholesterol and other lipid profile parameters. This study was done to evaluate the lipid metabolism in subclinical hypothyroidism.Methods: This case control study was done to compare the lipid profile parameters between subclinical and overt hypothyroidism cases attending the outpatient facility of our tertiary care hospital of our medical college in Puducherry. Newly diagnosed cases of hypothyroidism were selected by convenient sampling. A total of 37 SH cases and 31 overt hypothyroidism cases were included. Blood samples were drawn to measure lipid profile. A 2D echocardiogram was done to evaluate cardiac function. Ultrasonogram was done to evaluate fatty liver.Results: The mean age of the participants in the subclinical hypothyroidism group was 34.2±12.2 years while in the clinical hypothyroidism group was 35.7±9.8 years. About 13.5% of the participants in subclinical hypothyroidism group and 12.9% of the participants in clinical hypothyroidism had fatty liver in ultrasound. A significant difference was observed in the mean values of total cholesterol, triglycerides and LDL levels between clinical and subclinical hypothyroidism.Conclusions: This study highlights the need for screening of subclinical hypothyroidism in order to prevent the incidences of cardiovascular complications and other diseases like metabolic syndrome.


2016 ◽  
Vol 8 (2) ◽  
pp. 47-49
Author(s):  
Rona Laila ◽  
Nusrat Mahmud ◽  
Monnujan Nargis ◽  
TA Chowdhury

Polycystic ovary syndrome (PCOS) is one of the common disorders in women at child bearing age. The purpose of the present study was to investigate the lipid profile in patients with polycystic ovary syndrome. A total of 103 women with PCOS of 15-36 years of age were included in the present study. Of the 103 PCOS women, 50% were overweight or obese, 29.1% had impaired glucose tolerance (IGT) and 4.9% had type2 diabetes mellitus (T2DM). The mean BMI was generally higher (25.8±5.5 kg/m2). The mean serum cholesterol levels ranged from182 mg/dl to 236 mg/dl in all groups of women. The results of our study showed that women with PCOS had altered lipid profile and glycemic status. Therefore, evaluation of metabolic status is necessary for better management of women with PCOS.Ibrahim Med. Coll. J. 2014; 8(2): 47-49


Sign in / Sign up

Export Citation Format

Share Document